Multiple system atrophy (MSA) is a rare, progressive brain disease that damages the nervous system’s ability to control movement, balance, and automatic body functions like blood pressure and bladder control. It affects roughly 2 to 5 people per 100,000, with symptoms typically appearing around age 65. MSA belongs to the same family of diseases as Parkinson’s, but it progresses faster, responds poorly to Parkinson’s medications, and carries a median survival of about 8.6 years from symptom onset.
What Happens in the Brain
MSA is caused by the abnormal buildup of a protein called alpha-synuclein inside a specific type of brain cell called an oligodendrocyte. These cells normally produce the insulating coating around nerve fibers, which keeps signals moving efficiently. When alpha-synuclein clumps together inside them, it disrupts their ability to support and protect neurons. Over time, this leads to widespread nerve cell death in areas of the brain that control movement and automatic body functions.
The damage concentrates in two main regions. In one pattern, it hits the structures deep in the brain responsible for initiating and coordinating movement (the same areas affected in Parkinson’s disease). In the other, it targets the brainstem and cerebellum, which govern balance and coordination. The pattern of damage determines which type of MSA a person develops.
The Two Types: MSA-P and MSA-C
MSA is divided into two subtypes based on which movement symptoms dominate.
MSA-P (parkinsonian type) looks a lot like Parkinson’s disease on the surface. It causes slow, shuffling walking, muscle stiffness (especially in the neck and trunk), difficulty with balance, and quiet, slurred speech. Some people develop distinctive posture changes: the neck bending sharply forward, or the body tilting to one side while sitting. Tremor can occur but is usually mild and jerky, unlike the classic resting tremor of Parkinson’s.
MSA-C (cerebellar type) is defined by progressive loss of coordination and balance. People with this form have trouble with precise movements like reaching for objects or bringing food to their mouth. The tremor in MSA-C shows up during activity rather than at rest, which is another distinguishing feature from typical Parkinson’s.
Both types share the same underlying disease process, and both eventually develop significant problems with automatic body functions. The subtype simply reflects where the brain damage is most severe early on.
Autonomic Dysfunction: The Defining Feature
What truly separates MSA from Parkinson’s is how aggressively it attacks the autonomic nervous system, the network that runs blood pressure, bladder function, digestion, and other processes you never consciously think about. About 69% of MSA patients develop significant autonomic problems, compared to roughly 5% of people with Parkinson’s. These symptoms often appear within the first two years.
Blood Pressure Drops
Approximately 75% of people with MSA experience orthostatic hypotension, a sharp drop in blood pressure when standing up. The brain and body can’t properly signal blood vessels to tighten when you change positions, so blood pools in the legs and not enough reaches the brain. This causes dizziness, blurred vision, fainting, and a distinctive aching pain in the neck and shoulders sometimes called “coat hanger” pain because it follows the shape of a coat hanger across the upper back. Symptoms tend to be worst in the morning, partly because the body loses extra fluid overnight through increased urination.
Bladder Problems
Urinary urgency and frequency are among the earliest symptoms, often appearing in the first year. As the disease progresses, the bladder loses the ability to empty completely. About 70% of MSA patients eventually retain significant amounts of urine after using the bathroom and need catheterization, typically around four years after onset. The underlying problem is that the muscles controlling urine flow lose their coordination: the bladder contracts while the valve that should open simultaneously stays shut.
Sleep Disturbances
A sleep disorder called REM sleep behavior disorder frequently precedes the movement symptoms of MSA, sometimes by years. During REM sleep, the body normally paralyzes voluntary muscles to prevent you from acting out dreams. In MSA, that paralysis fails. People kick, punch, shout, or thrash during vivid dreams, sometimes injuring themselves or a bed partner. Loud snoring, sleep apnea, and a high-pitched breathing sound called stridor (caused by the vocal cords partially closing during sleep) are also common and can be serious. Sudden death during sleep is one of the major causes of mortality in MSA.
How MSA Differs From Parkinson’s Disease
Because MSA-P mimics Parkinson’s so closely, misdiagnosis is common in the early stages. Several “red flags” point toward MSA rather than typical Parkinson’s:
- Symmetrical onset. Parkinson’s almost always starts on one side of the body. MSA tends to affect both sides more evenly from the start.
- Rapid progression. People with MSA often need a walker or wheelchair within five years of their first symptoms. Parkinson’s typically progresses much more slowly.
- Poor response to levodopa. The standard Parkinson’s medication produces a clear improvement in most Parkinson’s patients. Only about 30% of MSA patients get any benefit, and it usually fades.
- Early falls and balance problems. Falls in the first year or two are unusual in Parkinson’s but common in MSA.
- Early, severe autonomic symptoms. Significant blood pressure drops, bladder dysfunction, or sexual dysfunction appearing early in the disease is a strong signal toward MSA.
- Vocal cord problems. Stridor and severe changes in voice quality are characteristic of MSA and rare in Parkinson’s.
Diagnosis
There is no single blood test or brain scan that confirms MSA during life. Diagnosis is based on the pattern of symptoms, particularly the combination of movement problems with early and prominent autonomic failure. MRI scans can sometimes show shrinkage in the brainstem or cerebellum, and autonomic testing can document the blood pressure and bladder abnormalities. A definitive diagnosis technically requires examining brain tissue after death, where the characteristic alpha-synuclein clumps inside oligodendrocytes can be seen under a microscope.
Treatment and Management
No treatment slows or stops MSA. Management focuses entirely on controlling symptoms and maintaining quality of life for as long as possible.
For blood pressure drops, the first-line approaches are practical: drinking extra fluids, increasing salt intake, wearing compression garments on the legs and abdomen, and sleeping with the head of the bed elevated. When these measures aren’t enough, two medications are specifically approved for this type of blood pressure problem. One works by tightening blood vessels directly. The other is a building block the body converts into the chemical messenger that normally signals blood vessels to constrict. Both have strong clinical evidence behind them.
Bladder symptoms may be managed with timed voiding schedules and, as the disease progresses, intermittent catheterization. Urinary tract infections become a serious and recurring concern. Up to 25% of MSA deaths are linked to complications from these infections.
Physical therapy plays a central role in maintaining mobility and reducing fall risk. Speech therapy can help with swallowing difficulties and the voice changes that often develop. Occupational therapy helps people adapt their daily routines as coordination declines.
Outlook and Progression
MSA follows a relatively predictable downward course. The median survival from the first symptom to death is about 8.6 years, though individual timelines vary. Most people experience a steady decline in mobility, with increasing dependence on assistive devices. Swallowing difficulties, breathing problems during sleep, and recurrent infections become the primary medical concerns in later stages. The leading causes of death are sudden cardiorespiratory arrest during sleep and complications from infections, particularly those involving the urinary tract.